Synaptogenix Stock Performance
| SNPX Stock | USD 2.72 0.01 0.37% |
The entity has a beta of 0.83, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, Synaptogenix's returns are expected to increase less than the market. However, during the bear market, the loss of holding Synaptogenix is expected to be smaller as well. At this point, Synaptogenix has a negative expected return of -0.26%. Please make sure to validate Synaptogenix's treynor ratio, accumulation distribution, as well as the relationship between the Accumulation Distribution and price action indicator , to decide if Synaptogenix performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Synaptogenix has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 37.5 M |
Synaptogenix |
Synaptogenix Relative Risk vs. Return Landscape
If you would invest 353.00 in Synaptogenix on August 29, 2024 and sell it today you would lose (81.00) from holding Synaptogenix or give up 22.95% of portfolio value over 90 days. Synaptogenix is currently does not generate positive expected returns and assumes 5.3496% risk (volatility on return distribution) over the 90 days horizon. In different words, 47% of stocks are less volatile than Synaptogenix, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Synaptogenix Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Synaptogenix's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Synaptogenix, and traders can use it to determine the average amount a Synaptogenix's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0493
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SNPX |
Estimated Market Risk
| 5.35 actual daily | 47 53% of assets are more volatile |
Expected Return
| -0.26 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.05 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Synaptogenix is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Synaptogenix by adding Synaptogenix to a well-diversified portfolio.
Synaptogenix Fundamentals Growth
Synaptogenix Stock prices reflect investors' perceptions of the future prospects and financial health of Synaptogenix, and Synaptogenix fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Synaptogenix Stock performance.
| Return On Equity | -0.075 | ||||
| Return On Asset | -0.14 | ||||
| Current Valuation | (18.08 M) | ||||
| Shares Outstanding | 1.36 M | ||||
| Price To Book | 0.29 X | ||||
| EBITDA | (8.31 M) | ||||
| Cash And Equivalents | 28.75 M | ||||
| Cash Per Share | 4.20 X | ||||
| Total Debt | 5.53 M | ||||
| Book Value Per Share | 14.99 X | ||||
| Cash Flow From Operations | (5.17 M) | ||||
| Earnings Per Share | 10.27 X | ||||
| Total Asset | 31.11 M | ||||
| Retained Earnings | (33.61 M) | ||||
About Synaptogenix Performance
Evaluating Synaptogenix's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Synaptogenix has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Synaptogenix has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. The company was incorporated in 2012 and is headquartered in New York, New York. Synaptogenix operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 4 people.Things to note about Synaptogenix performance evaluation
Checking the ongoing alerts about Synaptogenix for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Synaptogenix help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Synaptogenix generated a negative expected return over the last 90 days | |
| Synaptogenix has high historical volatility and very poor performance | |
| Synaptogenix has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (6.04 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Synaptogenix currently holds about 28.75 M in cash with (5.17 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.2, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Synaptogenix's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Synaptogenix's stock is overvalued or undervalued compared to its peers.
- Examining Synaptogenix's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Synaptogenix's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Synaptogenix's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Synaptogenix's stock. These opinions can provide insight into Synaptogenix's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Synaptogenix Stock Analysis
When running Synaptogenix's price analysis, check to measure Synaptogenix's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synaptogenix is operating at the current time. Most of Synaptogenix's value examination focuses on studying past and present price action to predict the probability of Synaptogenix's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synaptogenix's price. Additionally, you may evaluate how the addition of Synaptogenix to your portfolios can decrease your overall portfolio volatility.